Skopos Bio raises A$12M
Skopos Bio announced a Seed round of A$12M on 2 October 2026. The company operates in HealthTech and is based in Australia. It was founded by Michael Hofman, Co-founder, Professor and nuclear physician-scientist. Announced today.
Founder
Michael Hofman
Co-founder, Professor and nuclear physician-scientist, Skopos Bio
Outreach angles
- -Hofman led Peter MacCallum's proPSMA clinical trial, a prostate cancer study whose approach Novartis later commercialized.
- -Hofman is a nuclear physician-scientist who says he wants more than a paper in a scientific journal and aims to make treatments globally available.
- -The A$12M seed from Tenmile, Tin Alley Ventures and Yosemite will take the radiopharmaceutical therapy into human clinical trials.
Signals
SeedHealthcareDeep TechRegulated IndustryNew Market
Round details
Company: Skopos Bio
Domain: skoposbio.com
Amount: A$12M
Stage: Seed
Industry: HealthTech
Country: Australia
Announced: 2 October 2026
Other HealthTech raises
Recently funded in Australia